42 results on '"Kevin P Labadie"'
Search Results
2. Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses
- Author
-
Michael C Jensen, Katherine J Brempelis, Courtney M Cowan, Shannon A Kreuser, Kevin P Labadie, Brooke M Prieskorn, Nicole A P Lieberman, Chibawanye I Ene, Kara W Moyes, Harrison Chinn, Kole R DeGolier, Lisa R Matsumoto, Sara K Daniel, Jason K Yokoyama, Amira D Davis, Virginia J Hoglund, Kimberly S Smythe, Stephanie D Balcaitis, Richard G Ellenbogen, Jean S Campbell, Eric C Holland, and Courtney A Crane
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Background Though currently approved immunotherapies, including chimeric antigen receptor T cells and checkpoint blockade antibodies, have been successfully used to treat hematological and some solid tumor cancers, many solid tumors remain resistant to these modes of treatment. In solid tumors, the development of effective antitumor immune responses is hampered by restricted immune cell infiltration and an immunosuppressive tumor microenvironment (TME). An immunotherapy that infiltrates and persists in the solid TME, while providing local, stable levels of therapeutic to activate or reinvigorate antitumor immunity could overcome these challenges faced by current immunotherapies.Methods Using lentivirus-driven engineering, we programmed human and murine macrophages to express therapeutic payloads, including Interleukin (IL)-12. In vitro coculture studies were used to evaluate the effect of genetically engineered macrophages (GEMs) secreting IL-12 on T cells and on the GEMs themselves. The effects of IL-12 GEMs on gene expression profiles within the TME and tumor burden were evaluated in syngeneic mouse models of glioblastoma and melanoma and in human tumor slices isolated from patients with advanced gastrointestinal malignancies.Results Here, we present a cellular immunotherapy platform using lentivirus-driven genetic engineering of human and mouse macrophages to constitutively express proteins, including secreted cytokines and full-length checkpoint antibodies, as well as cytoplasmic and surface proteins that overcomes these barriers. GEMs traffic to, persist in, and express lentiviral payloads in xenograft mouse models of glioblastoma, and express a non-signaling truncated CD19 surface protein for elimination. IL-12-secreting GEMs activated T cells and induced interferon-gamma (IFNγ) in vitro and slowed tumor growth resulting in extended survival in vivo. In a syngeneic glioblastoma model, IFNγ signaling cascades were also observed in mice treated with mouse bone-marrow-derived GEMs secreting murine IL-12. These findings were reproduced in ex vivo tumor slices comprised of intact MEs. In this setting, IL-12 GEMs induced tumor cell death, chemokines and IFNγ-stimulated genes and proteins.Conclusions Our data demonstrate that GEMs can precisely deliver titratable doses of therapeutic proteins to the TME to improve safety, tissue penetrance, targeted delivery and pharmacokinetics.
- Published
- 2020
- Full Text
- View/download PDF
3. Correction: Short-course radiotherapy promotes pro-inflammatory macrophages via extracellular vesicles in human rectal cancer
- Author
-
Michael C Jensen, Katherine J Brempelis, Courtney M Cowan, Shannon A Kreuser, Kevin P Labadie, Brooke M Prieskorn, Nicole A P Lieberman, Chibawanye I Ene, Kara W Moyes, Harrison Chinn, Kole R DeGolier, Lisa R Matsumoto, Sara K Daniel, Jason K Yokoyama, Amira D Davis, Virginia J Hoglund, Kimberly S Smythe, Stephanie D Balcaitis, Richard G Ellenbogen, Jean S Campbell, Eric C Holland, and Courtney A Crane
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Published
- 2020
- Full Text
- View/download PDF
4. Pilot study of humanized glypican-3-targeted zirconium-89 immuno-positron emission tomography for hepatocellular carcinoma
- Author
-
Lindsay K. Dickerson, Adrienne L. Lehnert, Donald K. Hamlin, Kevin P. Labadie, Kristin E. Goodsell, Yongjun Liu, Yawen Li, D. Scott Wilbur, Robert Miyaoka, and James O. Park
- Subjects
Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Published
- 2024
- Full Text
- View/download PDF
5. A novel rat model for the study of postoperative pancreatic fistula
- Author
-
Alan F Utria, Kevin P Labadie, Arezou Abbasi, Xianyong Gui, Venu G Pillarisetty, James O Park, and Jonathan G Sham
- Subjects
Pancreatic Fistula ,Postoperative Complications ,General Veterinary ,Risk Factors ,Animals ,Animal Science and Zoology ,Pancreas ,Rats ,Pancreaticoduodenectomy - Abstract
While over the past several decades mortality after pancreatic surgery has decreased to
- Published
- 2022
6. Glypican-3 targeted positron emission tomography detects sub-centimeter tumors in a xenograft model of hepatocellular carcinoma
- Author
-
Kevin P. Labadie, Adrienne L Lehnert, Aimee L Kenoyer, Donald K Hamlin, Andrew D. Ludwig, Alan F. Utria, Sara K. Daniel, Tara N. Mihailovic, Alexander Prossnitz, Johnnie J. Orozco, Yawen Li, D. Scott Wilbur, Robert S. Miyaoka, and James O. Park
- Subjects
Radiology, Nuclear Medicine and imaging - Abstract
Background Early intrahepatic recurrence is common after surgical resection of hepatocellular carcinoma (HCC) and leads to increased morbidity and mortality. Insensitive and nonspecific diagnostic imaging contributes to EIR and results in missed treatment opportunities. In addition, novel modalities are needed to identify targets amenable for targeted molecular therapy. In this study, we evaluated a zirconium-89 radiolabeled glypican-3 (GPC3) targeting antibody conjugate (89Zr-αGPC3) for use in positron emission tomography (PET) for detection of small, GPC3+ HCC in an orthotopic murine model. Athymic nu/J mice received hepG2, a GPC3+ human HCC cell line, into the hepatic subcapsular space. Tumor-bearing mice were imaged by PET/computerized tomography (CT) 4 days after tail vein injection of 89Zr-αGPC3. Livers were then excised for the tumors to be identified, measured, bisected, and then serially sectioned at 500 μm increments. Sensitivity and specificity of PET/CT for 89Zr-αGPC3-avid tumors were assessed using tumor confirmation on histologic sections as the gold standard. Results In tumor-bearing mice, 89Zr-αGPC3 avidly accumulated in the tumor within four hours of injection with ongoing accumulation over time. There was minimal off-target deposition and rapid bloodstream clearance. Thirty-eight of 43 animals had an identifiable tumor on histologic analysis. 89Zr-αGPC3 immuno-PET detected all 38 histologically confirmed tumors with a sensitivity of 100%, with the smallest tumor detected measuring 330 μm in diameter. Tumor-to-liver ratios of 89Zr-αGPC3 uptake were high, creating excellent spatial resolution for ease of tumor detection on PET/CT. Two of five tumors that were observed on PET/CT were not identified on histologic analysis, yielding a specificity of 60%. Conclusions 89Zr-αGPC3 avidly accumulated in GPC3+ tumors with minimal off-target sequestration. 89Zr-αGPC3 immuno-PET yielded a sensitivity of 100% and detected sub-millimeter tumors. This technology may improve diagnostic sensitivity of small HCC and select GPC3+ tumors for targeted therapy. Human trials are warranted to assess its impact.
- Published
- 2023
7. Impact of neoadjuvant chemotherapy on the difficulty and outcomes of laparoscopic and robotic major liver resections for colorectal liver metastases: A propensity-score and coarsened exact-matched controlled study
- Author
-
Jacob Ghotbi, Davit Aghayan, Åsmund Fretland, Bjørn Edwin, Nicholas L. Syn, Federica Cipriani, Mohammed Alzoubi, Chetana Lim, Olivier Scatton, Tran Cong duy Long, Paulo Herman, Fabricio Ferreira Coelho, Marco V. Marino, Vincenzo Mazzaferro, Adrian K.H. Chiow, Iswanto Sucandy, Arpad Ivanecz, Sung-Hoon Choi, Jae Hoon Lee, Mikel Prieto, Marco Vivarelli, Felice Giuliante, Andrea Ruzzenente, Chee-Chien Yong, Mengqiu Yin, Constantino Fondevila, Mikhail Efanov, Zenichi Morise, Fabrizio Di Benedetto, Raffaele Brustia, Raffaele Dalla Valle, Ugo Boggi, David Geller, Andrea Belli, Riccardo Memeo, Alejandro Mejia, James O. Park, Fernando Rotellar, Gi-Hong Choi, Ricardo Robles-Campos, Xiaoying Wang, Robert P. Sutcliffe, Johann Pratschke, Chung-Ngai Tang, Charing C.N. Chong, Mathieu D'Hondt, Kazuteru Monden, Santiago Lopez-Ben, T. Peter Kingham, Alessandro Ferrero, Giuseppe Maria Ettorre, Giovanni Battista Levi Sandri, Franco Pascual, Daniel Cherqui, Xiao Liang, Alessandro Mazzotta, Go Wakabayashi, Mariano Giglio, Roberto I. Troisi, Ho-Seong Han, Tan-To Cheung, Atsushi Sugioka, Kuo-Hsin Chen, Rong Liu, Olivier Soubrane, David Fuks, Luca Aldrighetti, Mohammad Abu Hilal, Brian K.P. Goh, Mikel Gastaca, Juul Meurs, Celine De Meyere, Kit-Fai Lee, Kelvin K. Ng, Diana Salimgereeva, Ruslan Alikhanov, Lip-Seng Lee, Jae Young Jang, Yutaro Kato, Masayuki Kojima, Jaime Arthur Pirola Kruger, Victor Lopez-Lopez, Margarida Casellas I Robert, Roberto Montalti, Boram Lee, Mizelle D'Silva, Hao-Ping Wang, Mansour Saleh, Zewei Chen, Shian Yu, Simone Vani, Francesco Ardito, Ugo Giustizieri, Davide Citterio, Federico Mocchegiani, Marco Colasanti, Yoelimar Guzmán, Kevin P. Labadie, Maria Conticchio, Epameinondas Dogeas, Emanuele F. Kauffmann, Mario Giuffrida, Daniele Sommacale, Alexis Laurent, Paolo Magistri, Phan Phuoc Nghia, Kohei Mishima, Bernardo Dalla Valle, Felix Krenzien, Moritz Schmelzle, Prashant Kadam, Qu Liu, Eric C.H. Lai, Junhao Zheng, Tiing Foong Siow, and Fabio Forchino
- Subjects
Robotic liver resections ,Oncology ,Laparoscopic liver resections ,Major resections ,Settore MED/18 - CHIRURGIA GENERALE ,Surgery ,General Medicine ,Difficulty ,Neoadjuvant chemotherapy - Published
- 2023
8. Impact of body mass index on the difficulty and outcomes of laparoscopic left lateral sectionectomy
- Author
-
Zewei Chen, Mengqiu Yin, Junhao Fu, Shian Yu, Nicholas L. Syn, Darren W. Chua, T. Peter Kingham, Wanguang Zhang, Tijs J. Hoogteijling, Davit L. Aghayan, Tiing Foong Siow, Olivier Scatton, Paulo Herman, Marco V. Marino, Vincenzo Mazzaferro, Adrian K.H. Chiow, Iswanto Sucandy, Arpad Ivanecz, Sung Hoon Choi, Jae Hoon Lee, Mikel Prieto, Marco Vivarelli, Felice Giuliante, Andrea Ruzzenente, Chee-Chien Yong, Safi Dokmak, Constantino Fondevila, Mikhail Efanov, Zenichi Morise, Fabrizio Di Benedetto, Raffaele Brustia, Raffaele Dalla Valle, Ugo Boggi, David Geller, Andrea Belli, Riccardo Memeo, Salvatore Gruttadauria, Alejandro Mejia, James O. Park, Fernando Rotellar, Gi-Hong Choi, Ricardo Robles-Campos, Xiaoying Wang, Robert P. Sutcliffe, Johann Pratschke, Eric C.H. Lai, Charing C.N. Chong, Mathieu D'Hondt, Kazuteru Monden, Santiago Lopez-Ben, Qu Liu, Rong Liu, Alessandro Ferrero, Giuseppe Maria Ettorre, Federica Cipriani, Daniel Cherqui, Xiao Liang, Olivier Soubrane, Go Wakabayashi, Roberto I. Troisi, Tan-To Cheung, Yutaro Kato, Atsushi Sugioka, Ho-Seong Han, Tran Cong duy Long, David Fuks, Mohammad Abu Hilal, Luca Aldrighetti, Kuo-Hsin Chen, Bjørn Edwin, Brian K.P. Goh, Mikel Gastaca, Juul Meurs, Celine De Meyere, Kit-Fai Lee, Kelvin K. Ng, Diana Salimgereeva, Ruslan Alikhanov, Lip-Seng Lee, Jae-Young Jang, Masayuki Kojima, Jaime Arthur Pirola Kruger, Fabricio Ferreira Coelho, Victor Lopez-Lopez, Margarida Casellas I Robert, Roberto Montalti, Mariano Giglio, Mizelle D'Silva, Boram Lee, Hao-Ping Wang, Franco Pascual, Mansour Saleh, Simone Vani, Francesco Ardito, Ugo Giustizieri, Davide Citterio, Federico Mocchegiani, Giammauro Berardi, Marco Colasanti, Yoelimar Guzmán, Kevin P. Labadie, Maria Conticchio, Epameinondas Dogeas, Emanuele F. Kauffmann, Mario Giuffrida, Daniele Sommacale, Alexis Laurent, Paolo Magistri, Kohei Mishima, Moritz Schmelzle, Felix Krenzien, Prashant Kadam, Jacob Ghotbi, Åsmund Avdem Fretland, Fabio Forchino, Alessandro Mazzotta, Francois Cauchy, Chetana Lim, Bernardo Dalla Valle, Junhao Zheng, Phan Phuoc Nghia, and Graduate School
- Subjects
Minimally-invasive liver ,Oncology ,Left lateral sectionectomy ,Laparoscopic hepatectomy ,Laparoscopic liver ,Minimally-invasive hepatectomy ,Surgery ,General Medicine ,Body mass index - Abstract
Introduction: Currently, the impact of body mass index (BMI) on the outcomes of laparoscopic liver resections (LLR) is poorly defined. This study attempts to evaluate the impact of BMI on the peri-operative outcomes following laparoscopic left lateral sectionectomy (L-LLS). Methods: A retrospective analysis of 2183 patients who underwent pure L-LLS at 59 international centers between 2004 and 2021 was performed. Associations between BMI and selected peri-operative outcomes were analyzed using restricted cubic splines. Results: A BMI of >27kg/m2 was associated with increased in blood loss (Mean difference (MD) 21 mls, 95% CI 5–36), open conversions (Relative risk (RR) 1.13, 95% CI 1.03–1.25), operative time (MD 11 min, 95% CI 6–16), use of Pringles maneuver (RR 1.15, 95% CI 1.06–1.26) and reductions in length of stay (MD -0.2 days, 95% CI -0.3 to −0.1). The magnitude of these differences increased with each unit increase in BMI. However, there was a “U” shaped association between BMI and morbidity with the highest complication rates observed in underweight and obese patients. Conclusion: Increasing BMI resulted in increasing difficulty of L-LLS. Consideration should be given to its incorporation in future difficulty scoring systems in laparoscopic liver resections.
- Published
- 2023
9. Glypican-3–Targeted 227Th α-Therapy Reduces Tumor Burden in an Orthotopic Xenograft Murine Model of Hepatocellular Carcinoma
- Author
-
Donald K. Hamlin, Sara K. Daniel, Kevin P. Labadie, Andrew D. Ludwig, Delphine L. Chen, Heidi L. Kenerson, Chris Orvig, Yawen Li, Lily Li, Jonathan G. Sham, D. Scott Wilbur, Raymond S. Yeung, Aimee L. Kenoyer, Johnnie J. Orozco, James O. Park, and Alan F. Utria
- Subjects
Biodistribution ,business.industry ,medicine.medical_treatment ,Cancer ,medicine.disease ,Glypican 3 ,In vivo ,Hepatocellular carcinoma ,Radioimmunotherapy ,Radionuclide therapy ,Toxicity ,Cancer research ,Medicine ,Radiology, Nuclear Medicine and imaging ,business - Abstract
Hepatocellular carcinoma (HCC) is a significant cause of morbidity and mortality worldwide with limited therapeutic options for advanced disease. Targeted alpha therapy (TAT) is an emerging class of targeted cancer therapy in which alpha-particle-emitting radionuclides, such as thorium-227, are specifically delivered to cancer tissue. Glypican-3 (GPC3) is a cell surface glycoprotein highly expressed on HCC. In this study, we describe the development and in vivo efficacy of a 227Th-labeled GPC3 targeting antibody conjugate (227Th-octapa-αGPC3) for treatment of HCC in an orthotopic murine model. METHODS: The chelator p-SCN-Bn-H4octapa-NCS (octapa) was conjugated to a GPC3 targeting antibody (αGPC3) for subsequent 227Th radiolabeling (octapa-αGPC3). Conditions were varied to optimize radiolabeling of 227Th. In vitro stability was evaluated by measuring percentage of protein-bound 227Th by gamma-ray spectroscopy. An orthotopic athymic Nu/J murine model using HepG2 cells was developed. Biodistribution and blood clearance of 227Th-octapa-αGPC3 was evaluated in tumor bearing mice. Efficacy of 227Th-octapa-αGPC3 was assessed in tumor bearing animals with serial measurement of serum alpha-fetoprotein at 23 days after radionuclide injection. RESULTS: Octapa-conjugated αGPC3 provided up to 70% 227Th labeling yield in 2 h at room temperature. In the presence of ascorbate, ≥97.8% of 227Th was bound to αGPC3-octapa after 14 d in phosphate buffered saline. In HepG2 tumor-bearing mice, highly specific GPC3 targeting was observed, with significant 227Th-octapa-αGPC3 accumulation in the tumor over time and minimal accumulation in normal tissue. 23 days after treatment, significant reduction in tumor burden was observed in mice receiving 500 kBq/kg 227Th-octapa-αGPC3 by tail vein injection. No acute off-target toxicity was observed and no animals died prior to termination of the study. CONCLUSION:227Th-octapa-αGPC3 was observed to be stable in vitro, maintain high specificity for GPC3 with favorable biodistribution in vivo, and result in significant antitumor activity without significant acute off-target toxicity in an orthotopic murine model of HCC.
- Published
- 2021
10. Head Over Wheels: Traumatic Head and Neck Injuries Secondary to Mountain Biking
- Author
-
Chris Xiao, Merrick A Brodsky, Rijul S. Kshirsagar, Kevin P. Labadie, David W. Chou, Srikanth Krishnan, Ashton B Christian, and Jonathan Liang
- Subjects
Adult ,Male ,Facial trauma ,medicine.medical_specialty ,Head (watercraft) ,Injury control ,Mountain biking ,Poison control ,Occupational safety and health ,Neck Injuries ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Injury prevention ,Prevalence ,medicine ,Craniocerebral Trauma ,Humans ,030223 otorhinolaryngology ,Head and neck ,business.industry ,030229 sport sciences ,General Medicine ,Middle Aged ,medicine.disease ,United States ,Bicycling ,Hospitalization ,Otorhinolaryngology ,Physical therapy ,Female ,Emergency Service, Hospital ,business - Abstract
Objectives: The popularity of mountain biking (MTB) in the United States has risen in recent years. We sought to identify the prevalence and distribution of MTB associated head and neck injuries presenting to emergency departments across the U.S. and identify risk factors for hospital admission in this patient population. Methods: The National Electronic Injury Surveillance System (NEISS) was queried for MTB related injuries of the head and neck from 2009 to 2018, with analysis for incidence, age, gender, anatomic site, and diagnoses. Results: A total of 486 cases were identified, corresponding to an estimated 18 952 head and neck MTB related ED visits. Patients were predominantly male (80.7%) and white (69.8%) with a median age of 35 years (interquartile range, 21-46 years). A majority (88.4%) of patients were released from the ED, but a significant proportion of patients were admitted (9.2%) or transferred (1.2%). The most common facial fractures were facial/not specified (35%), nasal bone (29%), mandible (15%), orbit (12%), and zygomaxillary complex (9%). The greatest predictors of hospital admission/transfer were injury to the mouth or neck and avulsion-type injury ( P Conclusions: MTB results in a significant number of traumatic head and neck injuries nationwide. Patients are primarily adult, white males. The majority of injuries result in discharge from the ED, however a small amount of these patients experience significant morbidity necessitating hospital admission. Understanding the distribution of MTB head and neck injuries may aid in the clinical evaluation of these patients. Level of Evidence: 4
- Published
- 2021
11. Robotic Versus Laparoscopic Left and Extended Left Hepatectomy: An International Multicenter Study Propensity Score-Matched Analysis
- Author
-
Iswanto, Sucandy, Shlomi, Rayman, Eric C, Lai, Chung-Ngai, Tang, Yvette, Chong, Mikhail, Efanov, David, Fuks, Gi-Hong, Choi, Charing C, Chong, Adrian K H, Chiow, Marco V, Marino, Mikel, Prieto, Jae-Hoon, Lee, T Peter, Kingham, Mathieu, D'Hondt, Roberto I, Troisi, Sung Hoon, Choi, Robert P, Sutcliffe, Tan-To, Cheung, Fernando, Rotellar, James O, Park, Olivier, Scatton, Ho-Seong, Han, Johann, Pratschke, Xiaoying, Wang, Rong, Liu, Brian K P, Goh, and Kevin P, Labadie
- Subjects
Treatment Outcome ,Postoperative Complications ,Robotic Surgical Procedures ,Liver Neoplasms ,Humans ,Hepatectomy ,Laparoscopy ,Length of Stay ,Propensity Score ,Retrospective Studies - Abstract
Controversies exist among liver surgeons regarding clinical outcomes of the laparoscopic versus the robotic approach for major complex hepatectomies. The authors therefore designed a study to examine and compare the perioperative outcomes of laparoscopic left hepatectomy or extended left hepatectomy (L-LH/L-ELH) versus robotic left hepatectomy or extended left hepatectomy (R-LH/R-ELH) using a large international multicenter collaborative database.An international multicenter retrospective analysis of 580 patients undergoing L-LH/L-ELH or R-LH/R-ELH at 25 specialized hepatobiliary centers worldwide was undertaken. Propensity score-matching (PSM) was used at a 1:1 nearest-neighbor ratio according to 15 perioperative variables, including demographics, tumor characteristics, Child-Pugh score, presence of portal hypertension, multiple resections, histologic diagnosis, and Iwate difficulty grade.Before the PSM, 190 (32 %) patients underwent R-LH/R-ELH, and 390 (68 %) patients underwent L-LH/L-ELH. After the matching, 164 patients were identified in each arm without significant differences in demographics, preoperative variables, medical history, tumor pathology, tumor characteristics, or Iwate score. Regarding intra- and postoperative outcomes, the rebotic approach had significantly less estimated blood loss (EBL) (100 ml [IQR 200 ml] vs 200 ml [IQR 235 ml]; p = 0.029), fewer conversions to open operations (n = 4 [2.4 %] vs n = 13, [7.9 %]; p = 0.043), and a shorter hospital stay (6 days [IQR 3 days] vs 7 days [IQR 3.3 days]; p = 0.009).Both techniques are safe and feasible in major hepatic resections. Compared with L-LH/L-ELH, R-LH/R-ELH is associated with less EBL, fewer conversions to open operations, and a shorter hospital stay.
- Published
- 2022
12. IWATE criteria are associated with perioperative outcomes in robotic hepatectomy: a retrospective review of 225 resections
- Author
-
Kevin M. Sullivan, Alex W. Lois, Lindsay K. Dickerson, Sara K. Daniel, Raymond S. Yeung, Jonathan G. Sham, Kyle S. Bilodeau, James O. Park, Jaqueline Valdez Gonzalez, Alan F. Utria, Kevin P. Labadie, Venu G. Pillarisetty, David J. Droullard, Kathryn E. McNevin, John Calhoun, and Yongwoo D. Seo
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,030230 surgery ,Article ,03 medical and health sciences ,Postoperative Complications ,0302 clinical medicine ,Robotic Surgical Procedures ,Minimally invasive surgery ,Internal medicine ,Hepatectomy ,Humans ,Medicine ,Robotic surgery ,Intrahepatic Cholangiocarcinoma ,Robotic hepatectomy ,Retrospective Studies ,business.industry ,Liver Neoplasms ,Confounding ,Perioperative ,Length of Stay ,Hepatology ,medicine.disease ,Surgery ,Bile Ducts, Intrahepatic ,Bile Duct Neoplasms ,IWATE criteria ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Laparoscopy ,business ,Abdominal surgery - Abstract
Background Robotic hepatectomy (RH) is increasingly utilized for minor and major liver resections. The IWATE criteria were developed to classify minimally invasive liver resections by difficulty. The objective of this study was to apply the IWATE criteria in RH and to describe perioperative and oncologic outcomes of RH over the last decade at our institution. Methods Perioperative and oncologic outcomes of patients who underwent RH between 2011 and 2019 were retrospectively collected. The difficulty level of each operation was assessed using the IWATE criteria, and outcomes were compared at each level. Univariate linear regression was performed to characterize the relationship between IWATE criteria and perioperative outcomes (OR time, EBL, and LOS), and a multivariable model was also developed to address potential confounding by patient characteristics (age, sex, BMI, prior abdominal surgery, ASA class, and simultaneous non-hepatectomy operation). Results Two hundred and twenty-five RH were performed. Median IWATE criteria for RH were 6 (IQR 5–9), with low, intermediate, advanced, and expert resections accounting for 23% (n = 51), 34% (n = 77), 32% (n = 72), and 11% (n = 25) of resections, respectively. The majority of resections were parenchymal-sparing approaches, including anatomic segmentectomies and non-anatomic partial resections. 30-day complication rate was 14%, conversion to open surgery occurred in 9 patients (4%), and there were no deaths within 30 days postoperatively. In the univariate linear regression analysis, IWATE criteria were positively associated with OR time, EBL, and LOS. In the multivariable model, IWATE criteria were independently associated with greater OR time, EBL, and LOS. Two-year overall survival for hepatocellular carcinoma and intrahepatic cholangiocarcinoma was 94% and 50%, respectively. Conclusion In conclusion, the IWATE criteria are associated with surgical outcomes after RH. This series highlights the utility of RH for difficult hepatic resections, particularly parenchymal-sparing resections in the posterosuperior sector, extending the indication of minimally invasive hepatectomy in experienced hands and potentially offering select patients an alternative to open hepatectomy or other less definitive liver-directed treatment options.
- Published
- 2021
13. Factors associated with and impact of open conversion on the outcomes of minimally invasive left lateral sectionectomies: An international multicenter study
- Author
-
Hao Ping Wang, Chee Chien Yong, Andrew G.R. Wu, Daniel Cherqui, Roberto I. Troisi, Federica Cipriani, Davit Aghayan, Marco V. Marino, Andrea Belli, Adrian K.H. Chiow, Iswanto Sucandy, Arpad Ivanecz, Marco Vivarelli, Fabrizio Di Benedetto, Sung-Hoon Choi, Jae Hoon Lee, James O. Park, Mikel Gastaca, Constantino Fondevila, Mikhail Efanov, Fernando Rotellar, Gi-Hong Choi, Ricardo Robles Campos, Xiaoying Wang, Robert P. Sutcliffe, Johann Pratschke, Chung Ngai Tang, Charing C. Chong, Mathieu D’Hondt, Andrea Ruzzenente, Paolo Herman, T. Peter Kingham, Olivier Scatton, Rong Liu, Alessandro Ferrero, Giovanni Battista Levi Sandri, Olivier Soubrane, Alejandro Mejia, Santiago Lopez-Ben, Jasper Sijberden, Kazuteru Monden, Go Wakabayashi, Atsushi Sugioka, Tan-To Cheung, Tran Cong Duy Long, Bjorn Edwin, Ho-Seong Han, David Fuks, Luca Aldrighetti, Mohamed Abu Hilal, Brian K.P. Goh, Chung-Yip Chan, Nicholas Syn, Mikel Prieto, Henri Schotte, Celine De Meyere, Felix Krenzien, Moritz Schmelzle, Kit-Fai Lee, Diana Salimgereeva, Ruslan Alikhanov, Lip Seng Lee, Jae Young Jang, Kevin P. Labadie, Masayuki Kojima, Yutaro Kato, Asmund Avdem Fretland, Jacob Ghotbi, Fabricio Ferreira Coelho, Jaime Arthur Pirola Kruger, Victor Lopez-Lopez, Paolo Magistri, Bernardo Dalla Valle, Margarida Casellas I Robert, Kohei Mishima, Giuseppe Maria Ettorre, Federico Mocchegiani, Prashant Kadam, Franco Pascual, Mansour Saleh, Alessandro Mazzotta, Roberto Montalti, Mariano Giglio, Boram Lee, Mizelle D’Silva, Phan Phuoc Nghia, Chetana Lim, Qu Liu, Eric C. Lai, Wang, Hao Ping, Yong, Chee Chien, Wu, Andrew G R, Cherqui, Daniel, Troisi, Roberto I, Cipriani, Federica, Aghayan, Davit, Marino, Marco V, Belli, Andrea, Chiow, Adrian K H, Sucandy, Iswanto, Ivanecz, Arpad, Vivarelli, Marco, Di Benedetto, Fabrizio, Choi, Sung-Hoon, Lee, Jae Hoon, Park, James O, Gastaca, Mikel, Fondevila, Constantino, Efanov, Mikhail, Rotellar, Fernando, Choi, Gi-Hong, Campos, Ricardo Roble, Wang, Xiaoying, Sutcliffe, Robert P, Pratschke, Johann, Tang, Chung Ngai, Chong, Charing C, D'Hondt, Mathieu, Ruzzenente, Andrea, Herman, Paolo, Kingham, T Peter, Scatton, Olivier, Liu, Rong, Ferrero, Alessandro, Levi Sandri, Giovanni Battista, Soubrane, Olivier, Mejia, Alejandro, Lopez-Ben, Santiago, Sijberden, Jasper, Monden, Kazuteru, Wakabayashi, Go, Sugioka, Atsushi, Cheung, Tan-To, Long, Tran Cong Duy, Edwin, Bjorn, Han, Ho-Seong, Fuks, David, Aldrighetti, Luca, Abu Hilal, Mohamed, Goh, Brian K P, Wang, H. P., Yong, C. C., Wu, A. G. R., Cherqui, D., Troisi, R. I., Cipriani, F., Aghayan, D., Marino, M. V., Belli, A., Chiow, A. K. H., Sucandy, I., Ivanecz, A., Vivarelli, M., Di Benedetto, F., Choi, S. -H., Lee, J. H., Park, J. O., Gastaca, M., Fondevila, C., Efanov, M., Rotellar, F., Choi, G. -H., Campos, R. R., Wang, X., Sutcliffe, R. P., Pratschke, J., Tang, C. N., Chong, C. C., D'Hondt, M., Ruzzenente, A., Herman, P., Kingham, T. P., Scatton, O., Liu, R., Ferrero, A., Levi Sandri, G. B., Soubrane, O., Mejia, A., Lopez-Ben, S., Sijberden, J., Monden, K., Wakabayashi, G., Sugioka, A., Cheung, T. -T., Long, T. C. D., Edwin, B., Han, H. -S., Fuks, D., Aldrighetti, L., Abu Hilal, M., Goh, B. K. P., Chan, C. -Y., Syn, N., Prieto, M., Schotte, H., De Meyere, C., Krenzien, F., Schmelzle, M., Lee, K. -F., Salimgereeva, D., Alikhanov, R., Lee, L. S., Jang, J. Y., Labadie, K. P., Kojima, M., Kato, Y., Fretland, A. A., Ghotbi, J., Coelho, F. F., Pirola Kruger, J. A., Lopez-Lopez, V., Magistri, P., Valle, B. D., Casellas I Robert, M., Mishima, K., Ettorre, G. M., Mocchegiani, F., Kadam, P., Pascual, F., Saleh, M., Mazzotta, A., Montalti, R., Giglio, M., Lee, B., D'Silva, M., Nghia, P. P., Lim, C., Liu, Q., Lai, E. C., Graduate School, Surgery, and CCA - Cancer Treatment and Quality of Life
- Subjects
Male ,Operative Time ,Length of Stay ,Conversion to Open Surgery ,Hepatectomy ,Humans ,Minimally Invasive Surgical Procedures ,Postoperative Complications ,Retrospective Studies ,Treatment Outcome ,Hypertension, Portal ,Laparoscopy ,Neoplasms ,Hypertension ,Surgery ,Portal - Abstract
Background: Despite the rapid advances that minimally invasive liver resection has gained in recent decades, open conversion is still inevitable in some circumstances. In this study, we aimed to determine the risk factors for open conversion after minimally invasive left lateral sectionectomy, and its impact on perioperative outcomes. Methods: This is a post hoc analysis of 2,445 of 2,678 patients who underwent minimally invasive left lateral sectionectomy at 45 international centers between 2004 and 2020. Factors related to open conversion were analyzed via univariate and multivariate analyses. One-to-one propensity score matching was used to analyze outcomes after open conversion versus non-converted cases. Results: The open conversion rate was 69/2,445 (2.8%). On multivariate analyses, male gender (3.6% vs 1.8%, P = .011), presence of clinically significant portal hypertension (6.1% vs 2.6%, P = .009), and larger tumor size (50 mm vs 32 mm, P < .001) were identified as independent factors associated with open conversion. The most common reason for conversion was bleeding in 27/69 (39.1%) of cases. After propensity score matching (65 open conversion vs 65 completed via minimally invasive liver resection), the open conversion group was associated with increased operation time, blood transfusion rate, blood loss, and postoperative stay compared with cases completed via the minimally invasive approach. Conclusion: Male sex, portal hypertension, and larger tumor size were predictive factors of open conversion after minimally invasive left lateral sectionectomy. Open conversion was associated with inferior perioperative outcomes compared with non-converted cases.
- Published
- 2022
14. Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases
- Author
-
Kevin M Sullivan, Xiuyun Jiang, Prajna Guha, Christopher Lausted, Jason A Carter, Cynthia Hsu, Kevin P Labadie, Karan Kohli, Heidi L Kenerson, Sara K Daniel, Xiaowei Yan, Changting Meng, Arezou Abbasi, Marina Chan, Y David Seo, James O Park, Ian Nicholas Crispe, Raymond S Yeung, Teresa S Kim, Taranjit S Gujral, Qiang Tian, Steven C Katz, and Venu G Pillarisetty
- Subjects
Gastroenterology - Abstract
ObjectiveProgrammed cell death protein 1 (PD-1) checkpoint inhibition and adoptive cellular therapy have had limited success in patients with microsatellite stable colorectal cancer liver metastases (CRLM). We sought to evaluate the effect of interleukin 10 (IL-10) blockade on endogenous T cell and chimeric antigen receptor T (CAR-T) cell antitumour function in CRLM slice cultures.DesignWe created organotypic slice cultures from human CRLM (n=38 patients’ tumours) and tested the antitumour effects of a neutralising antibody against IL-10 (αIL-10) both alone as treatment and in combination with exogenously administered carcinoembryonic antigen (CEA)-specific CAR-T cells. We evaluated slice cultures with single and multiplex immunohistochemistry, in situ hybridisation, single-cell RNA sequencing, reverse-phase protein arrays and time-lapse fluorescent microscopy.ResultsαIL-10 generated a 1.8-fold increase in T cell-mediated carcinoma cell death in human CRLM slice cultures. αIL-10 significantly increased proportions of CD8+T cells without exhaustion transcription changes, and increased human leukocyte antigen - DR isotype (HLA-DR) expression of macrophages. The antitumour effects of αIL-10 were reversed by major histocompatibility complex class I or II (MHC-I or MHC-II) blockade, confirming the essential role of antigen presenting cells. Interrupting IL-10 signalling also rescued murine CAR-T cell proliferation and cytotoxicity from myeloid cell-mediated immunosuppression. In human CRLM slices, αIL-10 increased CEA-specific CAR-T cell activation and CAR-T cell-mediated cytotoxicity, with nearly 70% carcinoma cell apoptosis across multiple human tumours. Pretreatment with an IL-10 receptor blocking antibody also potentiated CAR-T function.ConclusionNeutralising the effects of IL-10 in human CRLM has therapeutic potential as a stand-alone treatment and to augment the function of adoptively transferred CAR-T cells.
- Published
- 2021
15. Hepatocellular carcinoma arising within a β-catenin mutated inflammatory hepatic adenoma
- Author
-
James O. Park, Camtu D. Truong, Christopher M Chandler, and Kevin P. Labadie
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Adenoma ,Hepatocellular carcinoma ,Inflammatory hepatic adenoma ,medicine.disease_cause ,Pathology and Forensic Medicine ,Malignant transformation ,Gross examination ,03 medical and health sciences ,Beta-catenin activation ,0302 clinical medicine ,Pathology ,Medicine ,RB1-214 ,Mutation ,business.industry ,Hepatic adenoma ,medicine.disease ,030104 developmental biology ,030220 oncology & carcinogenesis ,Catenin ,Cancer research ,Histopathology ,business ,Complication - Abstract
Hepatic adenomas are benign but carry risk of hemorrhage and malignant transformation, the latter complication being more common in those with β-catenin mutations. We report a case of hepatocellular carcinoma arising in a large inflammatory hepatic adenoma (9.2 cm) with β-catenin mutation. Gross pathology, radiology, and histopathology are shown. This case highlights the risk of malignant transformation that accompanies large tumor size, β-catenin activation, and reinforces the need for surgical intervention in such cases.
- Published
- 2021
16. Adjuvant Transcatheter Arterial Infusion Therapy for Hepatocellular Carcinoma: Not Yet for Everybody
- Author
-
Kevin P. Labadie and Jonathan G. Sham
- Subjects
medicine.medical_specialty ,business.industry ,medicine.medical_treatment ,MEDLINE ,medicine.disease ,Surgery ,Oncology ,Transcatheter arterial infusion ,Surgical oncology ,Hepatocellular carcinoma ,medicine ,business ,Adjuvant - Published
- 2020
17. Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma
- Author
-
Kevin M. Sullivan, Sara K. Daniel, Venu G. Pillarisetty, and Kevin P. Labadie
- Subjects
0301 basic medicine ,medicine.medical_treatment ,T cell ,Medicine (miscellaneous) ,Review ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,medicine ,Cytotoxic T cell ,Hypoxia ,Tumor microenvironment ,lcsh:R5-920 ,Solid tumor ,Chemistry ,Immunotherapy ,Pancreatic cancer ,030104 developmental biology ,Cytokine ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Cancer cell ,Cancer research ,Myeloid-derived Suppressor Cell ,Molecular Medicine ,lcsh:Medicine (General) - Abstract
Pancreatic ductal adenocarcinoma (PDA) is a lethal disease with limited response to cytotoxic chemoradiotherapy, as well as newer immunotherapies. The PDA tumor microenvironment contains infiltrating immune cells including cytotoxic T cells; however, there is an overall immunosuppressive milieu. Hypoxia is a known element of the solid tumor microenvironment and may promote tumor survival. Through various mechanisms including, but not limited to, those mediated by HIF-1α, hypoxia also leads to increased tumor proliferation and metabolic changes. Furthermore, epithelial to mesenchymal transition is promoted through several pathways, including NOTCH and c-MET, regulated by hypoxia. Hypoxia-promoted changes also contribute to the immunosuppressive phenotype seen in many different cell types within the microenvironment and thereby may inhibit an effective immune system response to PDA. Pancreatic stellate cells (PSCs) and myofibroblasts appear to contribute to the recruitment of myeloid derived suppressor cells (MDSCs) and B cells in PDA via cytokines increased due to hypoxia. PSCs also increase collagen secretion in response to HIF-1α, which promotes a fibrotic stroma that alters T cell homing and migration. In hypoxic environments, B cells contribute to cytotoxic T cell exhaustion and produce chemokines to attract more immunosuppressive regulatory T cells. MDSCs inhibit T cell metabolism by hoarding key amino acids, modulate T cell homing by cleaving L-selectin, and prevent T cell activation by increasing PD-L1 expression. Immunosuppressive M2 phenotype macrophages promote T cell anergy via increased nitric oxide (NO) and decreased arginine in hypoxia. Increased numbers of regulatory T cells are seen in hypoxia which prevent effector T cell activation through cytokine production and increased CTLA-4. Effective immunotherapy for pancreatic adenocarcinoma and other solid tumors will need to help counteract the immunosuppressive nature of hypoxia-induced changes in the tumor microenvironment. Promising studies will look at combination therapies involving checkpoint inhibitors, chemokine inhibitors, and possible targeting of hypoxia. While no model is perfect, assuring that models incorporate the effects of hypoxia on cancer cells, stromal cells, and effector immune cells will be crucial in developing successful therapies.
- Published
- 2019
18. Multidisciplinary approach for multifocal, bilobar hepatocellular carcinoma: A case report and literature review
- Author
-
Derek Khorsand, James O. Park, Kevin P. Labadie, Stephanie K. Schaub, Guy E. Johnson, and Smith Apisarnthanarax
- Subjects
medicine.medical_specialty ,Hepatology ,business.industry ,Hepatocellular carcinoma ,Multidisciplinary care ,medicine.disease ,digestive system diseases ,03 medical and health sciences ,0302 clinical medicine ,Multidisciplinary approach ,030220 oncology & carcinogenesis ,Case report ,Medicine ,030211 gastroenterology & hepatology ,Radiology ,business ,Liver cancer - Abstract
BACKGROUND Hepatocellular carcinoma (HCC) is the second most lethal malignancy worldwide. There has been virtually no change in the survivability of HCC in spite of improvement in therapies. Surgery is considered the ideal first, curative intervention, however most patients present in advanced stages with unresectable disease. Therefore, systemic and liver-directed non-operative therapies are initially offered to downstage the disease. To ensure optimal management, a multidisciplinary team approach is often warranted. Our case highlights the benefits of a multidisciplinary approach in a young woman with multifocal, bilobar HCC. CASE SUMMARY A 36-year-old Chinese woman with untreated hepatitis B was found to have large bilobar HCC during work up for abdominal pain. Her initial serum alpha-fetoprotein was significantly elevated to 311136 ng/mL. Computed tomography scan demonstrated bulky bilobar liver masses, consistent with intermediate stage HCC, Barcelona Clinic Liver Cancer Stage B. Her case was discussed and a personalized care plan was developed at the Multidisciplinary Center for Advanced Minimally Invasive Liver Oncologic Therapies at the University of Washington. She initially underwent bilobar transarterial chemoembolization with partial response of the left lobar tumor. Salvage hypofractionated proton beam radiation therapy was delivered to the right lobe followed by two additional transarterial chemoembolizations to the left lobe with good response. Finally, to remove left lobar residual disease, she was taken to the operating room for a left hepatectomy eleven months after her initial presentation. She continues to be without evidence of disease. CONCLUSION Coordinating the multiple HCC treatment modalities is complex and our case highlights the benefits of a multidisciplinary approach.
- Published
- 2019
19. Hypoxia-inducible lentiviral gene expression in engineered human macrophages
- Author
-
Harrison K Chinn, Jennifer L Gardell, Lisa R Matsumoto, Kevin P Labadie, Tara N Mihailovic, Nicole A P Lieberman, Amira Davis, Venu G Pillarisetty, and Courtney A Crane
- Subjects
Pharmacology ,Cancer Research ,Macrophages ,Lentivirus ,Immunology ,Gene Expression ,Cell Hypoxia ,Mice ,Oncology ,Tumor Microenvironment ,Animals ,Cytokines ,Humans ,Molecular Medicine ,Immunology and Allergy - Abstract
BackgroundHuman immune cells, including monocyte-derived macrophages, can be engineered to deliver proinflammatory cytokines, bispecific antibodies, and chimeric antigen receptors to support immune responses in different disease settings. When gene expression is regulated by constitutively active promoters, lentiviral payload gene expression is unregulated, and can result in potentially toxic quantities of proteins. Regulated delivery of lentivirally encoded proteins may allow localized or conditional therapeutic protein expression to support safe delivery of adoptively transferred, genetically modified cells with reduced capacity for systemic toxicities.MethodsIn this study, we engineered human macrophages to express genes regulated by hypoxia responsive elements included in the lentiviral promoter region to drive conditional lentiviral gene expression only under hypoxic conditions. We tested transduced macrophages cultured in hypoxic conditions for the transient induced expression of reporter genes and the secreted cytokine, interleukin-12. Expression of hypoxia-regulated genes was investigated both transcriptionally and translationally, and in the presence of human tumor cells in a slice culture system. Finally, hypoxia-regulated gene expression was evaluated in a subcutaneous humanized-mouse cancer model.ResultsEngineered macrophages were shown to conditionally and tranisently express lentivirally encoded gene protein products, including IL-12 in hypoxic conditions in vitro. On return to normoxic conditions, lentiviral payload expression returned to basal levels. Reporter genes under the control of hypoxia response elements were upregulated under hypoxic conditions in the presence of human colorectal carcinoma cells and in the hypoxic xenograft model of glioblastoma, suggesting utility for systemic engineered cell delivery capable of localized gene delivery in cancer.ConclusionsMacrophages engineered to express hypoxia-regulated payloads have the potential to be administered systemically and conditionally express proteins in tissues with hypoxic conditions. In contrast to immune cells that function or survive poorly in hypoxic conditions, macrophages maintain a proinflammatory phenotype that may support continued gene and protein expression when regulated by conditional hypoxia responsive elements and naturally traffic to hypoxic microenvironments, making them ideal vehicles for therapeutic payloads to hypoxic tissues, such as solid tumors. With the ability to fine-tune delivery of potent proteins in response to endogenous microenvironments, macrophage-based cellular therapies may therefore be designed for different disease settings.
- Published
- 2022
20. Glypican-3 targeted delivery of 89Zr and 90Y as a theranostic radionuclide platform for hepatocellular carcinoma
- Author
-
D. Scott Wilbur, Andrew D. Ludwig, Kevin P. Labadie, Sara K. Daniel, Johnnie J. Orozco, Kevin M. Sullivan, Donald K. Hamlin, Delphine L. Chen, Robert S. Miyaoka, Jonathan G. Sham, James O. Park, Aimee L. Kenoyer, Tara N. Mihailovic, Adrienne L. Lehnert, and Raymond S. Yeung
- Subjects
Treatment response ,Carcinoma, Hepatocellular ,Hepatocellular carcinoma ,Science ,medicine.medical_treatment ,Mice, Nude ,Serum alpha-fetoprotein ,Glypican 3 ,Article ,Mice ,03 medical and health sciences ,Drug Delivery Systems ,0302 clinical medicine ,Glypicans ,Cell Line, Tumor ,medicine ,Animals ,Humans ,Tissue Distribution ,Yttrium Radioisotopes ,030212 general & internal medicine ,Positron emission ,Precision Medicine ,Radioisotopes ,Multidisciplinary ,Molecular medicine ,biology ,business.industry ,Liver Neoplasms ,Radioimmunotherapy ,medicine.disease ,Xenograft Model Antitumor Assays ,Gross tumor volume ,Positron-Emission Tomography ,030220 oncology & carcinogenesis ,biology.protein ,Medicine ,Zirconium ,Radiopharmaceuticals ,Antibody ,business ,Nuclear medicine - Abstract
Glypican-3 (GPC3) is a tumor associated antigen expressed by hepatocellular carcinoma (HCC) cells. This preclinical study evaluated the efficacy of a theranostic platform using a GPC3-targeting antibody αGPC3 conjugated to zirconium-89 (89Zr) and yttrium-90 (90Y) to identify, treat, and assess treatment response in a murine model of HCC. A murine orthotopic xenograft model of HCC was generated. Animals were injected with 89Zr-labeled αGPC3 and imaged with a small-animal positron emission/computerized tomography (PET/CT) imaging system (immuno-PET) before and 30 days after radioimmunotherapy (RIT) with 90Y-labeled αGPC3. Serum alpha fetoprotein (AFP), a marker of tumor burden, was measured. Gross tumor volume (GTV) and SUVmax by immuno-PET was measured using fixed intensity threshold and manual segmentation methods. Immuno-PET GTV measurements reliably quantified tumor burden prior to RIT, strongly correlating with serum AFP (R2 = 0.90). Serum AFP was significantly lower 30 days after RIT in 90Y-αGPC3 treated animals compared to those untreated (p = 0.01) or treated with non-radiolabeled αGPC3 (p = 0.02). Immuno-PET GTV measurements strongly correlated with tumor burden after RIT (R2 = 0.87), and GTV of animals treated with 90Y-αGPC3 was lower than in animals who did not receive treatment or were treated with non-radiolabeled αGPC3, although this only trended toward statistical significance. A theranostic platform utilizing GPC3 targeted 89Zr and 90Y effectively imaged, treated, and assessed response after radioimmunotherapy in a GPC3-expressing HCC xenograft model.
- Published
- 2021
21. Robotic Hepatectomy
- Author
-
Kevin P. Labadie, Lindsay K. Dickerson, and James O. Park
- Published
- 2021
22. Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses
- Author
-
Shannon A Kreuser, Venu G. Pillarisetty, Robert H. Pierce, Nicole A P Lieberman, Courtney A. Crane, Michael C. Jensen, Stephanie Balcaitis, Kimberly S. Smythe, Lisa R Matsumoto, Kole DeGolier, Virginia Hoglund, Katherine J. Brempelis, Chibawanye I. Ene, Amira Davis, Kevin P. Labadie, Harrison Chinn, Richard G. Ellenbogen, Eric C. Holland, Jason K. Yokoyama, Brooke M Prieskorn, Kara White Moyes, Sara K. Daniel, Courtney M Cowan, and Jean S. Campbell
- Subjects
Cancer Research ,Chemokine ,medicine.medical_treatment ,Immunology ,cell engineering ,CD19 ,Mice ,Immune system ,Neoplasms ,medicine ,Tumor Microenvironment ,Immunology and Allergy ,Animals ,Humans ,RC254-282 ,Pharmacology ,Tumor microenvironment ,biology ,Immune Cell Therapies and Immune Cell Engineering ,Melanoma ,Macrophages ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Immunotherapy ,medicine.disease ,Chimeric antigen receptor ,Disease Models, Animal ,Oncology ,biology.protein ,Cancer research ,Molecular Medicine ,Genetic Engineering ,Ex vivo - Abstract
BackgroundThough currently approved immunotherapies, including chimeric antigen receptor T cells and checkpoint blockade antibodies, have been successfully used to treat hematological and some solid tumor cancers, many solid tumors remain resistant to these modes of treatment. In solid tumors, the development of effective antitumor immune responses is hampered by restricted immune cell infiltration and an immunosuppressive tumor microenvironment (TME). An immunotherapy that infiltrates and persists in the solid TME, while providing local, stable levels of therapeutic to activate or reinvigorate antitumor immunity could overcome these challenges faced by current immunotherapies.MethodsUsing lentivirus-driven engineering, we programmed human and murine macrophages to express therapeutic payloads, including Interleukin (IL)-12. In vitro coculture studies were used to evaluate the effect of genetically engineered macrophages (GEMs) secreting IL-12 on T cells and on the GEMs themselves. The effects of IL-12 GEMs on gene expression profiles within the TME and tumor burden were evaluated in syngeneic mouse models of glioblastoma and melanoma and in human tumor slices isolated from patients with advanced gastrointestinal malignancies.ResultsHere, we present a cellular immunotherapy platform using lentivirus-driven genetic engineering of human and mouse macrophages to constitutively express proteins, including secreted cytokines and full-length checkpoint antibodies, as well as cytoplasmic and surface proteins that overcomes these barriers. GEMs traffic to, persist in, and express lentiviral payloads in xenograft mouse models of glioblastoma, and express a non-signaling truncated CD19 surface protein for elimination. IL-12-secreting GEMs activated T cells and induced interferon-gamma (IFNγ) in vitro and slowed tumor growth resulting in extended survival in vivo. In a syngeneic glioblastoma model, IFNγ signaling cascades were also observed in mice treated with mouse bone-marrow-derived GEMs secreting murine IL-12. These findings were reproduced in ex vivo tumor slices comprised of intact MEs. In this setting, IL-12 GEMs induced tumor cell death, chemokines and IFNγ-stimulated genes and proteins.ConclusionsOur data demonstrate that GEMs can precisely deliver titratable doses of therapeutic proteins to the TME to improve safety, tissue penetrance, targeted delivery and pharmacokinetics.
- Published
- 2020
23. Robotic-assisted laparoscopic liver resection in hepatocellular carcinoma
- Author
-
Kevin P. Labadie, James O. Park, and Jonathan G. Sham
- Subjects
medicine.medical_specialty ,Oncology ,Hepatology ,Robotic assisted ,business.industry ,Hepatocellular carcinoma ,Medicine ,business ,medicine.disease ,Surgery ,Resection - Published
- 2020
24. Abstract 928: Glypican-3 targeted thorium-227 alpha therapy reduces tumor burden in an orthotopic xenograft model of hepatocellular carcinoma
- Author
-
Andrew D. Ludwig, Raymond S. Yeung, Johnnie J. Orozco, Chris Orvig, Donald K. Hamlin, Kevin P. Labadie, Delphine L. Chen, James O. Park, Aimee L. Kenoyer, Yawen Li, Lily Li, Heidi L. Kenerson, Alan F. Utria, Sara K. Daniel, and D. Scott Wilbur
- Subjects
Cancer Research ,biology ,medicine.diagnostic_test ,Radioimmunoconjugate ,business.industry ,Cancer ,medicine.disease ,Glypican 3 ,In vitro ,Flow cytometry ,Oncology ,In vivo ,Hepatocellular carcinoma ,medicine ,Cancer research ,biology.protein ,Antibody ,business - Abstract
The purpose of this study is to develop a thorium-227 (227Th) antibody radioimmunoconjugate targeting glypican-3 (GPC3) and to test its therapeutic efficacy in a hepatocellular carcinoma (HCC) orthotopic xenograft model. GPC3 targeting antibody (αGPC3) was conjugated to bifunctional chelator p-SCN-Bn-H4octapa (octapa), and αGPC3-octapa binding affinity for GPC3 was evaluated by flow cytometry. 227Th radiolabeling of this conjugate was optimized, and in vitro stability of 227Th-αGPC3-octapa was evaluated in PBS with and without free radical scavenging agent over 14 days. For in vivo evaluation, an orthotopic xenograft model was generated by hepatic subcapsular injection of human HCC HepG2 cells. In vivo biodistribution was assessed in blood, tumor and organs at 1, 7 and 21 days after tail vein injection of 227Th-αGPC3-octapa (500 KBq/kg). To test therapeutic efficacy, tumor-bearing animals were injected with 227Th-αGPC3-octapa (250 kBq/kg or 500 kBq/kg) and compared to an irrelevant control antibody, 227Th-αBHV1-octapa (500 kBq/kg), and to a no-treatment control. Tumor burden was assessed with serial serum alpha-fetoprotein (AFP) measurements, a marker of tumor burden validated in this model. Toxicity to 227Th-αGPC3-octapa was measured by serum comprehensive metabolic panel obtained 21 days after injection. GPC3 binding affinity was highest after conjugation of αGPC3 with 10 equivalents of octapa. The protein recovery from the conjugation process was >85%, and mass spectral analysis indicated an average of 3.3 octapa moieties per molecule of αGPC3-octapa. After two weeks, >98% of αGPC3-octapa and αBHV1-octapa had 227Th bound in the presence of scavenging agent. αGPC3-octapa maintained high affinity for GPC3 as measured by flow cytometry, indicating the octapa conjugation reaction did not alter immunoreactivity of αGPC3. In vivo, 227Th-αGPC3-octapa accumulated in the tumor over time and cleared from normal tissues with a %ID/g of In conclusion, we report the development of a GPC3 targeted thorium conjugate and demonstrate its in vivo therapeutic efficacy in a murine orthotopic xenograft model of hepatocellular carcinoma. Citation Format: Kevin P. Labadie, Donald K. Hamlin, Aimee Kenoyer, Sara K. Daniel, Alan F. Utria, Andrew D. Ludwig, Heidi L. Kenerson, Delphine L. Chen, Johnnie Orozco, Raymond S. Yeung, Lily Li, Chris Orvig, Yawen Li, D Scott Wilbur, James O. Park. Glypican-3 targeted thorium-227 alpha therapy reduces tumor burden in an orthotopic xenograft model of hepatocellular carcinoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 928.
- Published
- 2021
25. Laparoscopic vs Robotic Hepatectomy: A Propensity Score-Matched Analysis Accounting for Resection Complexity
- Author
-
James Perkins, Kevin M. Sullivan, Raymond S. Yeung, Jaqueline Valdez Gonzalez, Alex W. Lois, Sara K. Daniel, James O. Park, David J. Droullard, Kevin P. Labadie, and Kathryn E. McNevin
- Subjects
medicine.medical_specialty ,business.industry ,Propensity score matching ,Robotic hepatectomy ,medicine ,Surgery ,business ,Resection - Published
- 2020
26. IL-10 Blockade Promotes Tumor Death in Fibrolamellar Carcinoma
- Author
-
Sara K. Daniel, Venu G. Pillarisetty, Xiuyun Jiang, Kimberly J. Riehle, Teresa S. Kim, Raymond S. Yeung, Alan F. Utria, Kevin M. Sullivan, Heidi L. Kenerson, and Kevin P. Labadie
- Subjects
Interleukin 10 ,business.industry ,Cancer research ,Medicine ,Surgery ,business ,Fibrolamellar Carcinoma ,Blockade - Published
- 2020
27. Immuno-Pet Detects Sub-Centimeter Hepatocellular Carcinoma
- Author
-
R. Yeung, R. Miyaoka, D.S. Wilbur, Donald K. Hamlin, A. Lehnert, Aimee L. Kenoyer, Andrew D. Ludwig, J. Park, and Kevin P. Labadie
- Subjects
Pathology ,medicine.medical_specialty ,Centimeter ,Hepatology ,business.industry ,Hepatocellular carcinoma ,Gastroenterology ,medicine ,medicine.disease ,business ,Immuno pet - Published
- 2020
28. Digital 3-Dimensional Liver Model Aids In Surgical Planning For Liver Tumors
- Author
-
Kevin P. Labadie, J.O. Park, Kevin M. Sullivan, and M.E. Czerwonko
- Subjects
medicine.medical_specialty ,Hepatology ,Acquired immunodeficiency syndrome (AIDS) ,business.industry ,General surgery ,Gastroenterology ,medicine ,business ,medicine.disease ,Surgical planning - Published
- 2020
29. Interleukin-12 Producing Genetically Engineered Macrophages to Reinvigorate Antitumor Immunity Against Advanced Gastrointestinal Cancer
- Author
-
Venu G. Pillarisetty, Katherine J. Brempelis, Kevin P. Labadie, Kevin M. Sullivan, Sara K. Daniel, Raymond S. Yeung, Teresa S. Kim, Shannon A Kreuser, Courtney A. Crane, and Heidi K. Kenerson
- Subjects
Antitumor immunity ,business.industry ,Genetically engineered ,Cancer research ,Interleukin 12 ,medicine ,Surgery ,Gastrointestinal cancer ,medicine.disease ,business - Published
- 2019
30. Evaluating the Role of Hypoxia and CXCL12 in Anti-Tumor Immune Response to Pancreatic Adenocarcinoma
- Author
-
Teresa S. Kim, Sara K. Daniel, Venu G. Pillarisetty, Xiuyun Jiang, Kevin M. Sullivan, and Kevin P. Labadie
- Subjects
Antitumor activity ,Immune system ,business.industry ,medicine ,Cancer research ,Adenocarcinoma ,Surgery ,Hypoxia (medical) ,medicine.symptom ,medicine.disease ,business - Published
- 2019
31. Yttrium-90-Labeled Anti-Glypican 3 Radioimmunotherapy Halts Tumor Growth in an Orthotopic Xenograft Model of Hepatocellular Carcinoma
- Author
-
Donald K. Hamlin, Raymond S. Yeung, Kevin P. Labadie, D.S. Wilbur, Andrew D. Ludwig, Y. David Seo, James O. Park, Holly M. Nguyen, and Vimukta M. Mahadev
- Subjects
Hepatoblastoma ,Article Subject ,medicine.medical_treatment ,lcsh:RC254-282 ,Glypican 3 ,030218 nuclear medicine & medical imaging ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,medicine ,DOTA ,biology ,business.industry ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,digestive system diseases ,3. Good health ,Oncology ,chemistry ,030220 oncology & carcinogenesis ,Radioimmunotherapy ,Hepatocellular carcinoma ,Monoclonal ,Toxicity ,biology.protein ,Cancer research ,Antibody ,business ,Research Article - Abstract
Hepatocellular carcinoma (HCC) is the second most lethal malignancy globally and is increasing in incidence in the United States. Unfortunately, there are few effective systemic treatment options, particularly for disseminated disease. Glypican-3 (GPC3) is a proteoglycan cell surface receptor overexpressed in most HCCs and provides a unique target for molecular therapies. We have previously demonstrated that PET imaging using a 89Zr-conjugated monoclonal anti-GPC3 antibody (αGPC3) can bind to minute tumors and allow imaging with high sensitivity and specificity in an orthotopic xenograft mouse model of HCC and that serum alpha-fetoprotein (AFP) levels are highly correlated with tumor size in this model. In the present study, we conjugated 90Y, a high-energy beta-particle-emitting radionuclide, to our αGPC3 antibody to develop a novel antibody-directed radiotherapeutic approach for HCC. Luciferase-expressing HepG2 human hepatoblastoma cells were orthotopically implanted in the livers of athymic nude mice, and tumor establishment was verified at 6 weeks after implantation by bioluminescent imaging and serum AFP concentration. Tumor burden by bioluminescence and serum AFP concentration was highly correlated in our model. Yttrium-90 was conjugated to αGPC3 using the chelating agent 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) and injected via the tail vein into the experimental mice at a dose of 200 μCi/mouse or 300 μCi/mouse. Control mice received DOTA-αGPC3 without radionuclide. At 30 days after a single dose of the radioimmunotherapy agent, mean serum AFP levels in control animals increased dramatically, while animals treated with 200 μCi only experienced a minor increase, indicating cessation of tumor growth, and animals treated with 300 μCi experienced a reduction in serum AFP concentration, indicating tumor shrinkage. Mean tumor-bearing liver weight in control animals was also significantly greater than that in animals that received either dose of 90Y-αGPC3. These results were achieved without significant toxicity as measured by body condition scoring and body weight. The results of this preclinical pilot demonstrate that GPC3 can be used as a target for radioimmunotherapy in an orthotopic mouse model of HCC and may be a target of clinical significance, particularly for disseminated HCC.
- Published
- 2019
- Full Text
- View/download PDF
32. Surgical Resection in HCC
- Author
-
James O. Park, Kevin P. Labadie, and Kevin M. Sullivan
- Subjects
Surgical resection ,medicine.medical_specialty ,business.industry ,medicine ,business ,Surgery - Published
- 2018
33. Abstract 5545: Neutralization of interleukin-10 by genetically engineered macrophages increase cancer cell death in metastatic colorectal cancer
- Author
-
Sara K. Daniel, Courtney A. Crane, Shannon A Kreuser, Xiuyun Jiang, Katherine J. Brempelis, Kevin P. Labadie, and Venu G. Pillarisetty
- Subjects
Cancer Research ,Interleukin 10 ,Oncology ,business.industry ,Genetically engineered ,Colorectal cancer ,Cancer cell ,Cancer research ,Medicine ,business ,medicine.disease ,Neutralization - Abstract
Background Interleukin-10 (IL-10) is an immunosuppressive cytokine that inhibits innate and adaptive antitumor immune responses in the tumor microenvironment (TME). Antibody neutralization of IL-10 in organotypic tumor slice cultures (TSC) in colorectal cancer liver metastases (CRCLM) leads to cancer cell death through. To target IL-10 blockade to the TME, we genetically engineered macrophages (GEM) to produce an IL-10 neutralizing antibody which we hypothesized would reactivate tumor infiltrating immune cells and increase cancer cell death in TSC. Methods We created a lentiviral construct to transduce GEMs with a publicly available neutralizing IL-10 antibody sequence (BT-063). CD14+ monocytes were isolated from healthy donor peripheral blood mononuclear cells and differentiated into macrophages, which were transduced with lentivirus to create control (cGEMs) and anti-IL-10 GEMs (αIL10 GEMs). To test the efficacy of αIL10 GEMs, punch biopsies (6 mm) were obtained from resected CRCLM, sliced to 250 um thickness with a vibratome and placed in individual culture wells. Slices were treated in triplicates with either 20ug/mL of human monoclonal αIL10 (αIL10), 1e5 cGEMs or αIL10 GEMs + 20ug/mL αIL10. GEMs and tumor cells were visualized with a Leica SP8X confocal microscope and apoptosis was measured with SR-FLICA fluorescent poly-caspase assay kit. Supernatant interferon-gamma (IFN-γ) levels were measured with Bioplex immunoassay and IL-10 neutralizing antibody was quantified with an enzyme-linked immunosorbent assay. Results Allogenic GEMs were transduced with BT-063-T2A-CD19t at 31% efficiency. cGEMs and αIL10 GEMs persisted in tumor slice culture for at least 6 days. αIL10 GEM-treated slice cultures contained 6.6ng/mL and 6.5ng/mL of αIL10 antibody after 3 and 6 days, respectively. At day 6 in culture, cancer cell apoptosis was increased in the αIL10 treated groups with 7%, 15%, 25%, 31% and 39% of cells were apoptotic in the no treatment control, cGEM, αIL10, cGEM + αIL10 and αIL10 GEM groups, respectively (One-way ANOVA, p = 0.0004). Elevation in IFN-γ was observed on day 6 in slices treated cGEMs (7.2ng/mL+4.3) and αIL10 GEMs (9.2ng/mL+5) compared to isotype control. Conclusion GEMs transduced with lentivirus encoding IL-10 neutralizing antibody maintain its production and are associated with increased cancer cell apoptosis. Citation Format: Kevin P. Labadie, Shannon A. Kreuser, Katherine J. Brempelis, Xiuyun Jiang, Sara K. Daniel, Courtney A. Crane, Venu G. Pillarisetty. Neutralization of interleukin-10 by genetically engineered macrophages increase cancer cell death in metastatic colorectal cancer [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5545.
- Published
- 2020
34. In VitroEvaluation of LithAssist: A Novel Combined Holmium Laser and Suction Device
- Author
-
Michael del Junco, Michael Ordon, Achim Lusch, Renai Yoon, Kevin P. Labadie, and Zhamshid Okhunov
- Subjects
medicine.medical_specialty ,Time Factors ,Percutaneous ,business.industry ,Syringes ,Urology ,Body Weight ,Holmium laser ,Equipment Design ,Lasers, Solid-State ,Suction ,Lithotripsy, Laser ,Combined Modality Therapy ,Surgery ,Hardness ,Medicine ,In vitro study ,Urinary Calculi ,Stone removal ,business ,Nuclear medicine - Abstract
The aim of this in vitro study was to evaluate and compare a novel intracorporeal lithotripter, LithAssist (LA; Cook Medical, Bloomington, IN), with the Swiss LithoClast Ultra (SLU; Boston Scientific, Boston, MA) for the fragmentation and removal of artificial stones made of gypsum-based cement.Ten soft and 20 hard ultracal-30 (U-30) stones were fragmented using two lithotripters. We recorded the stone weight (grams) prior to placing them into a 60-mL syringe for fragmentation. We inserted a 30F percutaneous access sheath into the syringe and positioned the stone within its lumen. Next, we inserted the lithotripter into a right-angled nephroscope. We recorded the times required for first and complete stone disintegration, disintegration to 2 mm, and complete stone removal for each device. In addition, we recorded the stone mass following each minute of stone fragmentation.In total, we subjected 5 soft and 10 hard stones to SLU and LA, respectively. All soft stones were completely disintegrated and removed with both the SLU and LA device. For soft stones, disintegration to 2 mm (2.83±0.41 vs. 4.15±0.70 minutes, p=0.049), complete disintegration (3.18±0.20 vs. 6.40±1.95 minutes, p=0.038), and complete removal (3.30±0.22 vs. 8.82±1.05 minutes, p=0.001) were faster for the SLU compared with the LA. For hard stones, fragmentation was not accomplished with the SLU, whereas with the LA, mean time for first disintegration, disintegration to 2 mm, complete disintegration, and complete removal was 3.60±1.36, 7.25±3.33, 7.54±2.94, and 8.64±2.78 minutes, respectively.In this in vitro study, the SLU was more efficient for softer artificial stones, and the LA was more efficient for harder artificial stones.
- Published
- 2014
35. Abstract 3196: Combination immunotherapy with PD-1 and CXCR4 blockade activates antitumor immunity against pancreatic neuroendocrine tumors
- Author
-
Xiuyun Jiang, Kevin P. Labadie, Arezou Abbasi, David Seo, Raymond S. Yeung, Kevin Sullivan, Venu G. Pillarisetty, Sara K. Daniel, and Teresa S. Kim
- Subjects
Cancer Research ,medicine.drug_class ,business.industry ,medicine.medical_treatment ,T cell ,Immunotherapy ,Neuroendocrine tumors ,Monoclonal antibody ,medicine.disease ,medicine.anatomical_structure ,Immune system ,Oncology ,medicine ,Cancer research ,Cytotoxic T cell ,MTT assay ,business ,CD8 - Abstract
Introduction: Although pancreatic neuroendocrine tumors (PNET) are less common and less deadly than pancreatic adenocarcinoma, they remain a considerable source of morbidity and mortality. The cases increasingly discovered due to advanced cross sectional imaging and the majority of PNETs are malignant when diagnosed. Immunotherapy for PNET has not yet been successfully demonstrated, although we and others have previously shown that they often contain robust T cell infiltrates. We hypothesized that combined immunotherapy could reactivate endogenous antitumor activity in organotypic tumor slice cultures of human PNET. Methods: Human PNET tumors were collected from the operating room and 250μm slices were cut using a vibratome and place on 0.4μm pore size membrane inserts (6 tumors). Slice culture survival testing was conducted using immunohistochemistry (IHC), the 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay, or live immunofluorescence imaging. To test the combining immunotherapeutic effects, slices were treated with a PD-1 blocking monoclonal antibody or isotype control, with or without the CXCR4 inhibitor, AMD3100. For time-lapse live imaging, slices were stained with fluorescently conjugated antibodies for CD8 and EpCAM, as well as a reagent that binds to activated caspase 3/7 enzymes to indicate induction of apoptosis. The live slice was first imaged alone to serve as a non-treated control, then anti-PD1 antibody and AMD3100 were applied, and the slice imaged immediately afterward to monitor response after treatment. Results: We confirmed that cultured slices maintain their baseline morphology and architecture over 9 days in culture. The MTT assay showed stable metabolic activity over the same period. The demonstration of the live and dynamic microenvironment was performed first via live multicolor IF including PNET cells (EpCAM+) and immune cells (both CD45+ and CD4+ cells) within the microenvironment. IHC demonstrated 10% or 12% increased of cleaved-Caspase-3+ cells with combined PD-1 and CXCR4 blockade, as compared to control, after 2 days or 7 days in culture. To confirm the role of cytotoxic T cells, live stained slices were imaged before and after addition of PD-1 blockade and AMD3100. We demonstrated that caspase activation was increased in EpCAM+ cells proximal to CD8+ T cells immediately following combination drug treatment. Furthermore, CD8+ cells proximity to EPCAM+ cells ( Conclusion: Our study demonstrates that combination PD-1 and CXCR4 blockade enhances CD8+ T cell migration and antitumor activity in human PNET tumor slice cultures. Citation Format: Xiuyun Jiang, Kevin Sullivan, Kevin Labadie, Sara K. Daniel, David Seo, Arezou Abbasi, Teresa Kim, Raymond Yeung, Venu Pillarisetty. Combination immunotherapy with PD-1 and CXCR4 blockade activates antitumor immunity against pancreatic neuroendocrine tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3196.
- Published
- 2019
36. Abstract 4489: IL-10 blockade reactivates antitumor immunity in human colorectal cancer liver metastases
- Author
-
Xiuyun Jiang, Teresa S. Kim, Venu G. Pillarisetty, Kevin P. Labadie, Raymond S. Yeung, Changting Meng, Qiang Tian, Neda Jabbari, Yongwoo David Seo, Xiaowei Yan, Sara K. Daniel, Chris Lausted, Kevin M. Sullivan, and Heidi L. Kenerson
- Subjects
Cancer Research ,Tumor microenvironment ,business.industry ,Tumor-infiltrating lymphocytes ,Colorectal cancer ,H&E stain ,Cancer ,medicine.disease ,Immune system ,Oncology ,Antigen ,Cancer research ,Immunohistochemistry ,Medicine ,business - Abstract
Background: Colorectal cancer (CRC) is the 4th most common cancer in the US, and the liver is the most common site of metastatic disease. Immune checkpoint inhibitor therapy has not been successful in achieving a clinical response in most patients with CRC liver metastases (CRCLM). The liver is known to induce tolerance to foreign antigens as a result of immunosuppressive cytokines including IL-10. We hypothesized that blockade of IL-10 signaling in CRCLM would potentiate tumor infiltrating lymphocyte (TIL)-mediated tumor cell death. Methods: We performed single-cell RNA sequencing (scRNAseq) of CRCLM using the 10x platform to evaluate for expression of IL-10 or IL-10 receptor (IL-10R) RNA within the tumor (n=8). To confirm if the IL-10R protein was present within the tumor microenvironment (TME), we also performed immunohistochemistry (IHC) (n=3). In order to study the functional effects of IL-10 blockade, we utilized a tumor slice culture (TSC) model, which allows for the study of cancers with their intact TME including immune cells. For TSCs, cores (6 mm diameter) were taken from freshly resected sterile human CRCLM and cut to 250 µm thick slices using a vibratome (n=3). Duplicate slices were treated with either IgG control or anti-IL-10 monoclonal antibodies and cultured for up to 6 days. To evaluate for histological evidence of necrosis and cell apoptosis within the tumor slice, we stained slides with either hematoxylin and eosin (H&E) or cleaved-Caspase-3 (CC3). To gain insight into the activation state of TIL after treatment, we measured levels of cytokines within the culture supernatants. Results: We found by scRNAseq that that IL-10 was expressed by a subset of tumor-associated macrophages, and IL-10R was expressed by both CD4+ and CD8+ T cells as well as macrophages. We confirmed that IL-10R protein was present within the CRCLM TME by IHC, and IL-10R expression was distributed throughout the stroma in non-tumor cells. In TSC treated with anti-IL-10 antibody, CC3+ cells were found to be 82.8% of total cells, compared to 36.1% of control (p = 1 x 10-6) at day 6. These findings were consistent across all human tumor samples treated with IL-10 blockade versus control at all time points examined. Furthermore, IL-10 blockade led to histologic evidence of generalized necrosis compared to an intact TME seen in the control group. Analysis of cytokines released into the media confirmed that IL-10 was present in controls, but absent in slices blocked with anti-IL-10 antibody. We also found increased levels of granzyme B, IL-2, GM-CSF, and IL-18, as well as a reduction in the immune checkpoint receptor TIM3, after one day of IL-10 blockade in culture. Conclusion: Treatment of human CRCLM TSCs with anti-IL-10 antibody leads to a marked increase in immune-mediated cell death within the tumor. Our data suggest that IL-10 serves as a critical regulator of anti-tumor immunity in the CRCLM TME and may serve as an important immunotherapeutic target. Citation Format: Kevin M. Sullivan, Xiuyun Jiang, Yongwoo David Seo, Heidi L. Kenerson, Xiaowei Yan, Chris Lausted, Changting Meng, Neda Jabbari, Kevin P. Labadie, Sara K. Daniel, Qiang Tian, Teresa S. Kim, Raymond S. Yeung, Venu G. Pillarisetty. IL-10 blockade reactivates antitumor immunity in human colorectal cancer liver metastases [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4489.
- Published
- 2019
37. Multicenter External Validation and Comparison of Stone Scoring Systems in Predicting Outcomes After Percutaneous Nephrolithotomy
- Author
-
Thomas Tailly, Zhamshid Okhunov, John D. Denstedt, Husain Alenezi, Melissa Huynh, Hassan Razvi, Vincent G. Bird, Justin Amann, Brandon R Nadeau, Arthur D. Smith, Arash Akhavein, Kevin P. Labadie, Daniel Olvera-Posada, Jaime Landman, and Philippe D. Violette
- Subjects
Adult ,Male ,Risk ,medicine.medical_specialty ,Multivariate analysis ,Urology ,medicine.medical_treatment ,Operative Time ,030232 urology & nephrology ,Severity of Illness Index ,03 medical and health sciences ,Kidney Calculi ,0302 clinical medicine ,Postoperative Complications ,Severity of illness ,medicine ,Humans ,Postoperative Period ,Percutaneous nephrolithotomy ,Aged ,Nephrostomy, Percutaneous ,Retrospective Studies ,Receiver operating characteristic ,business.industry ,Area under the curve ,Retrospective cohort study ,Nomogram ,Length of Stay ,Middle Aged ,Prognosis ,Surgery ,Nomograms ,Logistic Models ,Treatment Outcome ,ROC Curve ,030220 oncology & carcinogenesis ,Area Under Curve ,Nephrostomy ,Multivariate Analysis ,Female ,business ,Algorithms - Abstract
Several scoring systems have recently emerged to predict stone-free rate (SFR) and complications after percutaneous nephrolithotomy (PCNL). We aimed to compare the most commonly used scoring systems (Guy's stone score, S.T.O.N.E. nephrolithometry, and CROES nomogram), assess their predictive accuracy for SFR and other postoperative variables, and develop a risk group stratification based on these scoring systems.We performed a retrospective review of patients who have had a PCNL at four academic institutions between 2006 and 2013. Primary outcome was SFR within 3 weeks of the surgery and secondary outcomes were operative time (OT), complications, and length of stay (LOS). We performed chi-squared, t-test, logistic, linear, and Poisson regressions, as well as receiver operating characteristics curve with area under the curve (AUC) calculation.We identified 586 patients eligible for analysis. Of these, 67.4% were stone free. Guy's, S.T.O.N.E., and CROES score were predictive of SFR on multivariable logistic regression (odds ratio [OR]: 1.398, 95% confidence interval [CI]: 1.056, 1.852, p = 0.019; OR: 1.417, 85% CI: 1.231, 1.631, p 0.001; OR: 0.993, 95% CI: 0.988, 0.998, p = 0.004) and have similar predictive accuracy with AUCs of 0.629, 0.671, and 0.646, respectively. On multivariable linear regression, only S.T.O.N.E. was an independent predictor of longer OT (β = 14.556, 95% CI: 12.453, 16.660, p 0.001). None of the scores were independent predictors of postoperative complications or a longer LOS. Poisson regression allowed for risk group stratification and showed the S.T.O.N.E. score and CROES nomogram to have the most distinct risk groups.The three evaluated scoring systems have similar predictive accuracy of SFR. S.T.O.N.E. has additional value in predicting OT. Risk group stratification can be used for patient counseling. Further research is needed to identify whether or not any is superior to the others with regard to clinical usefulness and predictive accuracy.
- Published
- 2016
38. PD51-01 MULTI-CENTRE EVALUATION AND COMPARISON OF STONE SCORING SYSTEMS IN PREDICTING OUTCOMES AFTER PERCUTANEOUS NEPHROLITHOTOMY
- Author
-
Justin Amann, Brandon R Nadeau, Vincent G. Bird, Husain Alenezi, Zhamshid Okhunov, Melissa Huynh, Philippe D. Violette, Kevin P. Labadie, Hassan Razvi, Daniel Olvera-Posada, Thomas Tailly, Arash Akhavein, John D. Denstedt, and Jaime Landman
- Subjects
medicine.medical_specialty ,business.industry ,Urology ,General surgery ,medicine.medical_treatment ,medicine ,Multi centre ,business ,Percutaneous nephrolithotomy - Published
- 2015
39. Evaluation and comparison of urolithiasis scoring systems used in percutaneous kidney stone surgery
- Author
-
Arash Akhavein, Zeph Okeke, Daniel M. Moreira, Jorge Moreno-Palacios, Zhamshid Okhunov, Arthur D. Smith, Kevin P. Labadie, Vincent G. Bird, Jaime Landman, and Michael del Junco
- Subjects
Male ,medicine.medical_specialty ,Multivariate analysis ,Percutaneous ,Urology ,medicine.medical_treatment ,Logistic regression ,Kidney Calculi ,Urolithiasis ,Predictive Value of Tests ,medicine ,Humans ,Percutaneous nephrolithotomy ,Nephrostomy, Percutaneous ,Retrospective Studies ,Analysis of Variance ,business.industry ,Diagnostic Techniques, Urological ,Nomogram ,Middle Aged ,medicine.disease ,Surgery ,Cohort ,Nephrostomy ,Kidney stones ,Female ,business - Abstract
Purpose: Contemporary predictive tools for percutaneous nephrolithotomy outcomes include the Guy stone score, S.T.O.N.E. nephrolithometry and the CROES nephrolithometric nomogram. We compared each scoring system in the same cohort to determine which was most predictive of surgical outcomes. Methods: We retrospectively reviewed the records of patients who underwent percutaneous nephrolithotomy between 2009 and 2012 at a total of 3 academic institutions. We calculated the Guy stone score, the S.T.O.N.E. nephrolithometry score and the CROES nephrolithometric nomogram score based on preoperative computerized tomography images. A single observer at each institution reviewed all images and assigned scores. Univariate and multivariate analysis was done to determine the most predictive scoring system. Results: We enrolled 246 patients in study. In stone-free patients vs those with residual stones the mean Guy score was 2.2 vs 2.7, the mean S.T.O.N.E. score was 8.3 vs 9.5 and the mean CROES nomogram score was 222 vs 187 (each p
- Published
- 2014
40. Glypican-3 targeted delivery of 89Zr and 90Y as a theranostic radionuclide platform for hepatocellular carcinoma
- Author
-
Kevin P. Labadie, Andrew D. Ludwig, Adrienne L. Lehnert, Donald K. Hamlin, Aimee L. Kenoyer, Kevin M. Sullivan, Sara K. Daniel, Tara N. Mihailovic, Jonathan G. Sham, Johnnie J. Orozco, Raymond S. Yeung, Delphine L. Chen, D. Scott Wilbur, Robert S. Miyaoka, and James O. Park
- Subjects
Medicine ,Science - Abstract
Abstract Glypican-3 (GPC3) is a tumor associated antigen expressed by hepatocellular carcinoma (HCC) cells. This preclinical study evaluated the efficacy of a theranostic platform using a GPC3-targeting antibody αGPC3 conjugated to zirconium-89 (89Zr) and yttrium-90 (90Y) to identify, treat, and assess treatment response in a murine model of HCC. A murine orthotopic xenograft model of HCC was generated. Animals were injected with 89Zr-labeled αGPC3 and imaged with a small-animal positron emission/computerized tomography (PET/CT) imaging system (immuno-PET) before and 30 days after radioimmunotherapy (RIT) with 90Y-labeled αGPC3. Serum alpha fetoprotein (AFP), a marker of tumor burden, was measured. Gross tumor volume (GTV) and SUVmax by immuno-PET was measured using fixed intensity threshold and manual segmentation methods. Immuno-PET GTV measurements reliably quantified tumor burden prior to RIT, strongly correlating with serum AFP (R 2 = 0.90). Serum AFP was significantly lower 30 days after RIT in 90Y-αGPC3 treated animals compared to those untreated (p = 0.01) or treated with non-radiolabeled αGPC3 (p = 0.02). Immuno-PET GTV measurements strongly correlated with tumor burden after RIT (R 2 = 0.87), and GTV of animals treated with 90Y-αGPC3 was lower than in animals who did not receive treatment or were treated with non-radiolabeled αGPC3, although this only trended toward statistical significance. A theranostic platform utilizing GPC3 targeted 89Zr and 90Y effectively imaged, treated, and assessed response after radioimmunotherapy in a GPC3-expressing HCC xenograft model.
- Published
- 2021
- Full Text
- View/download PDF
41. Hepatocellular carcinoma arising within a β-catenin mutated inflammatory hepatic adenoma
- Author
-
Christopher M. Chandler, Kevin P. Labadie, James O. Park, and Camtu D. Truong
- Subjects
Hepatic adenoma ,Hepatocellular carcinoma ,Beta-catenin activation ,Inflammatory hepatic adenoma ,Malignant transformation ,Pathology ,RB1-214 - Abstract
Hepatic adenomas are benign but carry risk of hemorrhage and malignant transformation, the latter complication being more common in those with β-catenin mutations. We report a case of hepatocellular carcinoma arising in a large inflammatory hepatic adenoma (9.2 cm) with β-catenin mutation. Gross pathology, radiology, and histopathology are shown. This case highlights the risk of malignant transformation that accompanies large tumor size, β-catenin activation, and reinforces the need for surgical intervention in such cases.
- Published
- 2021
- Full Text
- View/download PDF
42. Protocol for tissue slice cultures from human solid tumors to study therapeutic response
- Author
-
Heidi L. Kenerson, Kevin M. Sullivan, Kevin P. Labadie, Venu G. Pillarisetty, and Raymond S. Yeung
- Subjects
Cell culture ,Cell-based Assays ,Cancer ,High Throughput Screening ,Immunology ,Science (General) ,Q1-390 - Abstract
Summary: The impact of systemic therapy on the tumor microenvironment has been difficult to study in human solid tumors. Our protocol describes steps for establishing slice cultures to investigate response to chemotherapies, immunotherapies, or adoptive cell therapies. Endpoints include changes in viability, histology, live-cell imaging, and multi-omics analyses. The protocol has been applied to a broad array of gastrointestinal malignancies. Culture conditions and treatment parameters can be modified for specific experiments. The platform is highly flexible and easy to manipulate.For complete details on the use and execution of this protocol, please refer to Kenerson et al. (2020), Jabbari et al. (2020), Brempelis et al. (2020), and Jiang et al. (2017).
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.